Legacy Bridge’s CRISPR Therapeutics CRSP Stock Holding History

Legacy Bridge’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.18K	Hold	40	–	–	﹤0.01%	311
2026 Q1	$1.9K	Buy	+40	New	+$2.11K	﹤0.01%	309

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Legacy Bridge's CRSP Position: Q2 2026 in Review

Legacy Bridge held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 40 shares worth $2.18K. The position accounts for ﹤0.01% of the portfolio, ranked #311.

Legacy Bridge first reported a position in CRSP in Q1 2026 and has held it in 2 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Legacy Bridge held 40 shares of CRISPR Therapeutics worth $2.18K as of Q2 2026.
Legacy Bridge left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of Legacy Bridge's portfolio in Q2 2026, its #311 holding.
Legacy Bridge first reported a position in CRISPR Therapeutics in Q1 2026 and has held it in 2 quarters since.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Legacy Bridge's 13F filing for Q2 2026, filed 13 Aug 2026.